Trial · NCT03124459
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Frequency of Adverse Events | Part 1 Cohort 1 (150 mg) | 6 | Participants | ||
| Part 1: Frequency of Adverse Events | Part 1 Cohort 2 (200 mg) | 5 | Participants | ||
| Part 1: Frequency of Adverse Events | Part 1 Cohort 3 (240 mg) | 6 | Participants | ||
| Part 2: Percent Change in Muscle Volume to the End of the Double-blind Placebo-controlled Portion of the Study. | Part 2 (Double-blind Placebo Controlled) Placebo Arm | 2.2 | Standard Error 4.1 | percent change | |
| Part 2: Percent Change in Muscle Volume to the End of the Double-blind Placebo-controlled Portion of the Study. | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | 15.8 | Standard Error 4.3 | percent change | |
| Part 2: Absolute Change in Amount of Intramuscular Fat Tissue to the End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) Placebo Arm | 1 | Standard Error 1.8 | mm3 | |
| Part 2: Absolute Change in Amount of Intramuscular Fat Tissue to the End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | -2.1 | Standard Error 1.9 | mm3 | |
| Part 2: Percent Change in Muscle Strength to the End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) Placebo Arm | -3.4 | Standard Error 19.8 | percent change | |
| Part 2: Percent Change in Muscle Strength to the End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | 32.0 | Standard Error 19.8 | percent change | |
| Part 2: Percent Change in Muscle Function - Walk/Run Time to the End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) Placebo Arm | -10.1 | Standard Error 4.7 | Percent change | |
| Part 2: Percent Change in Muscle Function - Walk/Run Time to the End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | -8.2 | Standard Error 4.7 | Percent change | |
| Part 2: Percent Change in Muscle Function - Walk Distance Assessed at the End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) Placebo Arm | 6 | Standard Error 4 | Percent change | |
| Part 2: Percent Change in Muscle Function - Walk Distance Assessed at the End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | 9.1 | Standard Error 3.8 | Percent change | |
| Part 2: Change in Balance and Fall Risk at the End of the Double-blind Placebo-controlled Portion of the Study. | Part 2 (Double-blind Placebo Controlled) Placebo Arm | Baseline | 52.8 | Standard Deviation 1.99 | score on scale |
| Part 2: Change in Balance and Fall Risk at the End of the Double-blind Placebo-controlled Portion of the Study. | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | Baseline | 50.8 | Standard Deviation 5.58 | score on scale |
| Part 2: Change in Balance and Fall Risk at the End of the Double-blind Placebo-controlled Portion of the Study. | Part 2 (Double-blind Placebo Controlled) Placebo Arm | Day 190 | 53 | Standard Deviation 2.77 | score on scale |
| Part 2: Change in Balance and Fall Risk at the End of the Double-blind Placebo-controlled Portion of the Study. | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | Day 190 | 51.4 | Standard Deviation 5.6 | score on scale |
| Part 2: Percent Change in Balance and Fall Risk From Baseline to the End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) Placebo Arm | 0.4 | Standard Deviation 3.59 | percent change in score on scale | |
| Part 2: Percent Change in Balance and Fall Risk From Baseline to the End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) ACE-083 Arm | 1.3 | Standard Deviation 3.13 | percent change in score on scale | |
| Part 2: Change in Clinical Examination Score From Baseline to End of the Double-blind Placebo-controlled Portion of the Study | Part 2 (Double-blind Placebo Controlled) Placebo Arm | Baseline | 10.1 | Standard Deviation 3.4 | score on scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03124459/results